drugset
drugset / Trial / NCT04899518

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04899518 ↗

Phase 2/3 Completed 922 enrolled Allysta Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease

Timeline

Start
2021-05-19
Primary completion
2023-03-14
Completion
2023-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject ALY688 Unknown 0.4 % —
Subject ALY688 Unknown 1 % —

Indications

dry eye syndrome